SCHEMBL16756407

SCHEMBL16756407

Cc1nc2ccc(-c3ccc(=O)[nH]c3)cc2n1Cc1cc(Cl)ccc1OC(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.44
HTT P42858 2/20 0.44
TSHR P16473 2/20 0.44
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
PLA2G1B P04054 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
ATG4B Q9Y4P1 1/20 0.40
KCNH2 Q12809 2/20 0.39
AOC3 Q16853 1/20 0.38
BRD4 O60885 3/20 0.35
GRIN2B Q13224 2/20 0.35
GRIN1 Q05586 1/20 0.35
P2RX3 P56373 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16756351 0.88 MEN1 (0.48) HPGDHTTTSHRALDH1A1KDM4E
SCHEMBL16756275 0.80 GRIN1 (0.47) BRD4GRIN2BGRIN1
SCHEMBL16756385 0.80 GALR3 (0.41) HPGDHTTTSHRMEN1KMT2A
SCHEMBL16756381 0.78 BRD4 (0.45) HPGDTSHRALDH1A1KDM4EMEN1
SCHEMBL18918983 0.76 MEN1 (0.43) HPGDHTTTSHRALDH1A1KDM4E
SCHEMBL16756414 0.76 MEN1 (0.43) HTTALDH1A1KDM4EMEN1KMT2A
SCHEMBL16756331 0.74 HPGD (0.40) HPGDHTTTSHRMEN1KMT2A
SCHEMBL24258034 0.74 KCNH2 (0.69) HTTALDH1A1KDM4EMEN1KMT2A
SCHEMBL16756282 0.73 GPR6 (0.39) GRIN2BGRIN1PDE4B
SCHEMBL16756279 0.73 GPR6 (0.39) GRIN2BGRIN1PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2858983-B1 TNF-ALPHA MODULATING BENZIMIDAZOLES UCB BIOPHARMA SPRL (BE) 2018-04-18 EP disclosed
US-9550737-B2 TNF -α modulating benzimidazoles UCB BIOPHARMA SPRL (BE) 2017-01-24 US disclosed
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles UCB BIOPHARMA SPRL (BE) 2015-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles TNF, TNFRSF1A, NFKBIA HPGD 1362/4885HTT 1177/4885TSHR 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.